Patent US5047229A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5047229A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment of cardiovascular and cerebral toxicity using calcium modulators

Assignee: Bayer Corp
•
Filing: 1986-12-17
•
Granted: 1991-09-10
•
Expires: 2006-12-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Calcium modulators can be effectively used to treat cardiovascular and cerebral toxicity induced by materials that alter the normal interaction of neurotransmitters with the calcium transport mechanisms of myocardial and cerebral cells. For example, calcium modulators can be used as an antidote to the lethal and chronic toxicity of cocaine and related indirectly acting sympathomimetic amines, imipramine and other tricyclic antidepressants, ganglionic stimulating drugs, and other toxic substances such as organophosphorus compounds that cause accumulations of neurotransmitters. Calcium modulators can also be used as an antidote to substances whose toxicity is based upon anticholinesterase activity. In addition, calcium modulators can be used as antagonists to the various types of toxic substances.

Inventors

  • 👤 Gabriel G. Nahas
  • 👤 Renaud Trouve

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 17:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61K31/13; A61K31/135; A61K31/275; A61K31/40; A61K31/435; A61K31/44; A61K31/445; A61K31/46; A61K31/495; A61K45/00; A61K45/06

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 64 words
A method for treating cardiovascular toxicity induced by a tricyclic antidepressant that induces a toxic effect by altering the normal interaction of neurotransmitters with the calcium ion metabolism of myocardial cells, comprising administering to a host intoxicated with the toxic material a compound which inhibits constriction of arteries in vitro in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 2
Independent Claim 64 words
A method for treating cardiovascular toxicity induced by a tricyclic antidepressant that induces a toxic effect by altering the normal interaction of neurotransmitters with the calcium ion metabolism of myocardial cells, comprising administering to a host intoxicated with the toxic material a compound which inhibits constriction of arteries in vitro in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 3
Dependent Claim 30 words
A method according to claim 1, wherein the compound administered is selected from the group consisting of verapamil, bepridil, nifedipine, diltiazem, cinnarizine, flunarizine, perhexiline, prenylamine, nitrendipine, nimodipine, nicardipine, and lidoflazine.
Claim 4
Independent Claim 64 words
A method for treating cerebral toxicity induced by a tricyclic antidepressant that induces a toxic effect by altering the normal interaction of neurotransmitters with the calcium ion metabolism of cerebral cells, comprising administering to a host intoxicated with the toxic material a compound which inhibits constriction of arteries in vitro in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 5
Independent Claim 64 words
A method for treating cerebral toxicity induced by a tricyclic antidepressant that induces a toxic effect by altering the normal interaction of neurotransmitters with the calcium ion metabolism of cerebral cells, comprising administering to a host intoxicated with the toxic material a compound which inhibits constriction of arteries in vitro in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 6
Dependent Claim 30 words
A method according to claim 3, wherein the compound administered is selected from the group consisting of verapamil, bepridil, nifedipine, diltiazem, cinnarizine, flunarizine, perhexiline, prenylamine, nitrendipine, nimodipine, nicardipine, and lidoflazine.
Claim 7
Dependent Claim 19 words
A method according to claim 1, wherein the host is intoxicated with a lethal dose of the toxic material.
Claim 8
Dependent Claim 19 words
A method according to claim 3, wherein the host is intoxicated with a lethal dose of the toxic material.
Claim 9
Dependent Claim 14 words
A method according to claim 1, wherein the compound administered is nimodipine or flunarizine.
Claim 10
Dependent Claim 14 words
A method according to claim 1, wherein the compound administered is nimodipine or flunarizine.
Claim 11
Independent Claim 40 words
A method for treating cardiovascular toxicity induced by imipramine comprising administering to a host intoxicated with imipramine a compound which inhibits constriction of arteries in vivo in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 12
Independent Claim 40 words
A method for treating cardiovascular toxicity induced by imipramine comprising administering to a host intoxicated with imipramine a compound which inhibits constriction of arteries in vivo in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 13
Dependent Claim 30 words
A method according to claim 9, wherein the compound administered is selected from the group consisting of verapamil, bepridil, nifedipine, diltiazem, cinnarizine, flunarizine, perhexiline, prenylamine, nitrendipine, nimodipine, nicardipine, and lidoflazine.
Claim 14
Independent Claim 40 words
A method for treating cerebral toxicity induced by imipramine comprising administering to a host intoxicated with imipramine a compound which inhibits constriction of arteries in vivo in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 15
Independent Claim 40 words
A method for treating cerebral toxicity induced by imipramine comprising administering to a host intoxicated with imipramine a compound which inhibits constriction of arteries in vivo in the presence of a neurotransmitter in an amount effective to treat the toxicity.
Claim 16
Dependent Claim 30 words
A method according to claim 11, wherein the compound administered is selected from the group consisting of verapamil, bepridil, nifedipine, diltiazem, cinnarizine, flunarizine, perhexiline, prenylamine, nitrendipine, nimodipine, nicardipine, and lidoflazine.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-09-09 1995-03-11 1995-09-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-09-09 1999-03-11 1999-09-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-09-09 2003-03-11 2003-09-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag